For the month ended 30 April 2026, Uni-Bio Science Group Limited reported unchanged capital metrics. Authorised share capital was steady at HKD 5.00 billion, representing 500.00 billion ordinary shares with a par value of HKD 0.01 each.

The issued share base also remained flat: 5.97 billion ordinary shares were in issue at both the beginning and end of the month, with no treasury shares held or cancelled. Consequently, there was no equity dilution and no funds were raised during the period.

Uni-Bio confirmed compliance with the Main Board’s minimum public-float requirement of 25%, ensuring at least one-quarter of its shares remain in public hands.

Share options granted under the 2016 Share Option Scheme totalled 420.59 million units outstanding at month-end. Exercise prices for these options range from HKD 0.066 to HKD 0.1714, and no options were exercised in April.

The company reported zero warrants, convertibles, or other share-issuance arrangements during the month. In addition, there were no movements in treasury shares and no Hong Kong Depositary Receipts in issue.

Overall, April 2026 was characterised by stability in Uni-Bio’s share capital structure, with robust public-float compliance and a sizeable, yet entirely unexercised, option pool under the longstanding 2016 scheme.